April 4, 2012—Drug manufacturer Eli Lilly and Co. is limiting sales of its widely used atypical antipsychotic Zyprexa (olanzapine) in light of the drug’s 340B ceiling price falling to $0.01 under the Office of Pharmacy Affairs’ (OPA) “penny pricing” policy.
The company notified OPA that it was instituting the purchasing limits in a March 28 letter that OPA posted on its home page on April 2. It marks the first time that a manufacturer has announced an allocation system for one of its products since OPA clarified its penny-pricing policy last November.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)